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Abstract 
In this work we have developed a multi-tiered computational platform to study protein-drug 
interactions. At the beginning of the workflow more efficient and less accurate methods are used to 
enable large libraries of proteins in many conformations and massive chemical libraries to be 
screened.  At each subsequent step in the workflow a subset of input data is investigated with 
increased accuracy and more computationally expensive methods. We demonstrate the developed 
workflow with the investigation of the lymphocyte-specific kinase LCK, which is implicated as a drug 
target in many cancers and also known to have toxic effects when unintentionally targeted. Several 
LCK states and conformations are investigated using molecular docking and generalized Born and 
surface area continuum solvation (MM/GBSA). Different variations in the drug screening process 
provide unique results that may elucidate the biological mechanisms underlying the drug interactions. 
1 Introduction 
The development of new pharmaceuticals is a lengthy, expensive, and sometimes fatal process 
when toxic drugs make it to the clinical trial phase. With the number of potential drug targets, the 
genetic variations that exist in those targets, and the large chemical space of potential drugs, a full 
understanding of all these possibilities will never be realized experimentally, making computational 
methods extremely important to improve the drug discovery and development process. Many 
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computational methods exist to examine protein target and drug interactions, often with a huge trade-
off between efficiency and accuracy, with the accuracy still being very dependent on the system being 
studied. This study looks at a multi-tiered approach of using a more efficient method to do an initial 
virtual screen of a chemical library and a theoretically more accurate method on a top-scoring subset 
from the initial screen. The test protein under investigation is lymphocyte-specific kinase LCK, an 
SRC-family protein implicated as a drug target in many cancers and also known to have toxic effects 
when unintentionally targeted. We have built models of several conformations, performed a first tier 
of molecular docking calculations using benchmark data, and done initial development of second tier 
calculations using molecular mechanics energies combined with generalized Born and surface area 
continuum solvation (MM/GBSA). This significant research will help alleviate the current economic 
burden of developing new pharmaceuticals by innovatively utilizing massive computational power 
and address important public health concerns by providing safer and more affordable drugs. 
SRC-family proteins consist of conserved SRC homology (SH) domains starting from the C-
terminus, SH1 (kinase, catalytic domain), SH2 (phosphotyrosine recognition region), SH3 (proline-
motif recognition region), followed by a unique domain. Crystal structures of the LCK SH1, SH2, 
SH3, and combined SH2 and SH3 domains exist but not of all three complexed together. Several 
studies have evaluated the use of homology modeling and molecular docking for kinase drug design 
(Rockey & Elcock, 2006; Tuccinardi, Botta, Giordano, & Martinelli, 2010).  To our knowledge, no in 
depth computational modelling efforts have been done to generate three-dimensional structures of 
LCK conformations (active and inactive) including all three SH domains, all of which have been 
targeted in drug discovery (Lee et al., 2010; Scapin, 2002; Zellefrow et al., 2006). In this study we 
build models of LCK, test them for usefulness in docking studies using a benchmark set of active and 
decoy compounds, and set-up an automated workflow to increase accuracy of docking calculations 
using MM/GBSA (Graves et al., 2008; Greenidge, Kramer, Mozziconacci, & Wolf, 2012; Rastelli, 
Degliesposti, Del Rio, & Sgobba, 2009; Zhang, Wong, & Lightstone, 2014). The plan is to use a 
multi-tiered approach of calculations allowing to screen massively large chemical libraries. The first 
step will be virtual screening with the very efficient but not as accurate molecular docking. Top 
scoring hits from this step will be used in an MM/GBSA screening. Here we report some initial 
findings using MM/GBSA as a second tier screening. 
2  Methods 
Multiple homology models are built to represent the active state, the inactive state, and the DFG-
out inactive state. Molecular dynamics is performed on each model and snapshots are selected from 
the trajectory using RMSD based clustering of each frame. Docking is performed using the Database 
of Useful Decoys - Enhanced (DUD-E) compounds (Mysinger, Carchia, Irwin, & Shoichet, 2012) and 
enrichment plots are generated for each conformation. Then select sets of compounds and structures 
are rescored using MM/GBSA. The entire workflow is shown in Figure 1. Information on how to run 
each step of the workflow can be found at https://github.com/Xiaofei-Zhang.  
 
 
Figure 1: Graphical depiction of entire workflow 
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2.1 Modeling 
The LCK structure was generated using the UniProt primary sequence of human LCK (accession 
number P06239-1; (Koga et al., 1986; Perlmutter et al., 1988)) as input for the SWISS-MODEL 
Alignment Tool (Arnold, Bordoli, Kopp, & Schwede, 2006). Only residues 65 (or 67 depending on 
the PDB template) to 509 were used, as these correspond to the SH regions discussed above. Four 
models were built as described in the following. 1) Based on PDB structure 1QCF (Schindler et al., 
1999). This structure is of HCK and chosen based on sequence identity. This model is of the inactive 
state. 2) Based on PDB structure 2SRC (Xu, Doshi, Lei, Eck, & Harrison, 1999). This structure is of 
c-SRC, a related protein in the SRC-like family. This model is also of the inactive state. 3) Based on 
PDB structure 1Y57 (Cowan-Jacob et al., 2005). This structure is of c-SRC in the active state. 4) 
Based on PDB structure 1QCF (Schindler et al., 1999) for the structure as a whole and then the 
coordinates for the kinase domain are swapped with that of 2PL0 (Jacobs, Caron, & Hare, 2008). 
2PL0 is a structure of the kinase domain of LCK with imatinib bound. This model is of the inactive 
state with a DFG-out conformation. Sometimes residues at the C-terminus were excluded, including 
507, 508, and 509. The C-terminus was extended using Chimera (Pettersen et al., 2004). Added 
residues were then assigned the most stable rotameric configurations based on the Dunbrack library in 
Chimera (Dunbrack, 2002). Protonation states of residues were identified using Protoss (Bietz, 
Urbaczek, Schulz, & Rarey, 2014). 
 
 
 
Figure 2: Docking enrichment plots for the DUD-e LCK dataset for each model and selected snapshot. Only 
early enrichment is shown. 
 2.2 Ensemble Docking 
In order to do ensemble docking, molecular dynamics are first done on the resulting LCK models. 
The homology model was prepared using the combined CHARMM22 proteins/CHARMM27 nucleic 
acids topology and parameter files (MacKerell Jr et al., 1998). Phosphorylation of TYR 505 was 
accomplished using the par_all27_prot_na.inp and top_all27_prot_na.inp preparation files (Feng, 
Philippopoulos, MacKerell, & Lim, 1996). MD simulations were run using NAMD 2.10 (Phillips et 
al., 2005). Before production runs, the system was subject to 400 steps of minimization, 3000 steps of 
Berendsen thermostat/barostat equilibration, 100 steps of further minimization, and 3000 steps of 
Langevin thermostat/barostat equilibration. Then, one 100 ns production run was performed for each 
structure using Langevin thermodynamics. All time steps were 2 femtoseconds (fs), and frames from 
the production run were saved every 2 picoseconds (ps). Periodic boundary conditions and Particle 
Mesh Ewald (PME) electrostatics were used for all above MD procedures with an electrostatics cutoff 
of 12 Å. Seven to eight snapshots from the 100 ns production trajectory were chosen for each model 
based on clustering results from GROMOS (Christen et al., 2005).  
Active and decoy compounds for LCK were obtained from DUD-E (Mysinger et al., 2012). 
Docking was performed using the AutoDock Vina (Trott & Olson, 2010) docking engine and 
VinaMPI (Ellingson, Smith, & Baudry, 2013), a virtual screening tool that allows one to perform a 
massive number of docking calculations using high performance computing resources. Scripts were 
used for automated preparation of pdbqt files. The binding site was determined using the position 
where imatinib, a known inhibitor of LCK is bound in a crystal structure (PDB ID: 2PL0 (Jacobs et 
al., 2008)). After docking, ranked lists of compounds, in which the top of the list has compounds 
 
 
Figure 3: MM/GBSA and docking enrichment plots  
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predicted to bind the best, are generated using the docking score for each selected snapshot of each 
cluster. 
2.3 MM/GBSA 
Docking scores from Vina have a small range and therefore a large number of compounds have 
the same score. Instead of rescoring an exact percent of each ranked list a cut-off energy value is 
chosen to have a list of compounds for rescoring that is the top 4-5% of each list. Prior to MM/GBSA 
calculations, minimizations on the protein-ligand conformations predicted from docking structures 
were performed using AMBER 12 and AmberTools (Case et al., 2005; Pearlman et al., 1995). 
Antechamber, parmchk and tleap tools were used in order to generate parameter files for the ligands. 
Complexes were then solvated in tleap using TIP3P explicit waters and 0.15 M KCl. The system was 
then subject to 2000 steps of minimization. The protein was held fixed for the first 1000 steps, while 
everything was mobile in the last 1000 steps. MM/GBSA calculations were then performed on the 
post-minimization structure for each complex. MM/GBSA is performed on the snapshots that come 
from the two largest clusters representing conformations in which the protein remained in the longest 
during MD simulations and from one shorter lived conformation that had a better docking enrichment 
than other conformations as this conformation may be important for drug binding. Multiple ways of 
combining MM/GBSA scores from multiple docking poses were evaluated. Parameters were set to 
output 20 docking poses, but sometimes less than 20 poses are generated if they are not significantly 
different. Because of the best early enrichment and similar results using other models and clusters, the 
average of the best 5 scores from processing all generated docking poses is used in all following 
MM/GBSA calculations. 
3 Results 
The DUD-e active and decoy datasets were docked to each snapshot extracted from the MD 
trajectories for each model and enrichment plots are given in Figure 2. The figures only display the 
top 10% of the ranked compounds as we are interested in improving early enrichment in order to 
create experimental test sets that are highly enriched with active compounds. The total AUC for each 
cluster is given in the legend though. It can be seen that the snapshot from the first cluster (longest 
lived conformation) never has the best AUC. All the models have snapshots that have better than 
random enrichments. However, the 2PL0 model only has one snapshot that gets better than average 
enrichment overall. 
The MM/GBSA results are given in Figure 3. The MM/GBSA calculations are only done on the 
top 4-5% of compounds from each cluster. This is because of the computational time to do the 
calculations and to test whether or not it can be a step in a multi-tiered approach that increases the 
enrichment on subsets of data slightly enriched in previous steps. A docking curve is included on the 
plot for comparison. The line given here is an average between the maximum and minimum docking 
values obtained from placing all actives before and after the decoys with the same energy. The 2PL0 
model gets the best improvement using MM/GBSA and 1QCF has consistently better enrichment 
using MM/GBSA over docking. The performance of MM/GBSA over docking for the 2SRC and 
1Y57 models is not as good and at times is actually worse. 
To further test the worth of ensemble docking, different binding calculations, and the use of 
multiple models, we investigated the number of unique actives found using different clusters, models, 
and methods which can be seen in Figure 4. The Venn diagrams in the left-most box shows the 
overlap of compounds identified in the top 10% of different clusters for each model and method. It 
can be seen that identified actives are most often specific to a particular snapshot. A union is done for 
the list of actives identified in each cluster and the overlap of actives identified within different 
models is given in the top right box. Then a union is done for the list of actives identified in each 
model and the overlap of actives identified with different methods is given in the bottom right.  
4 Discussion 
Protein kinases, one of the largest families of proteins in higher eukaryotes, have over 900 protein 
products and contribute to a diversity of cellular processes (Anamika, Garnier, & Srinivasan, 2009). 
Protein kinases transfer a phosphate group from a bound ATP molecule to another protein substrate 
and regulate the majority of cellular pathways and signal transduction. Since kinase activity is so 
integral for normal cellular function, the deregulation of kinases has been implicated in many disease 
states, especially in cancers. Additionally, due to the high similarity in both sequence and structure 
between many kinases, kinase selectivity is a huge challenge for drug discovery. This in turn leads to 
off target effects that may be extremely toxic if drugs additionally interact with kinases that are 
normally expressed and not implicated in the given disease in which the drug is intended to relieve. 
The SRC family are nonreceptor tyrosine kinases and include c-SRC, LCK, HCK, FYN, BLK, 
LYN, FGR, YES, and YRK. The lymphocyte-specific protein tyrosine kinase (LCK) is critical in T 
cell development and activation and is expressed through most of the T cell lifespan and at a 
somewhat constant rate through their development (Palacios & Weiss, 2004). LCK has implications, 
as suggested above, as both a drug target and also a serious off-target in which to avoid unintended 
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interactions. In fact, LCK is the kinase agreed upon by several pharmaceutical companies in a 
consensus minimal toxicity screen. They link LCK activation to T cell activation and LCK inhibition 
to T cell inhibition and severe (SCID)-like immunodeficiency which is characterized by devastating 
deficiencies in cellular and humoral immunity (Bowes et al., 2012; Goldman et al., 1998). LCK is a 
protooncogene (Abraham, Levin, Marth, Forbush, & Perlmutter, 1991) and overexpressed in Burkitt 
(Jücker, Abts, Eick, Lenoir, & Tesch, 1991), non-Hodgkin’s B cell lymphoma (Knethen, Abts, Kube, 
Diehl, & Tesch, 1997), and lymphocytic leukemias (Majolini et al., 1998). High expression of LCK in 
chronic lymphocytic leukemia is linked with lymphocytic cell survival and thus studies suggest using 
LCK specific inhibitors for the treatment of progressive chronic lymphocytic leukemia (Talab, Allen, 
Thompson, Lin, & Slupsky, 2013). It has also been shown that inhibiting LCK enhances the ability 
for glucocorticoids to treat lymphoid malignancy, reversing glucocorticoid resistance (Harr et al., 
2010). As many anticancer therapeutics are associated with severe adverse reactions and kinases are 
implicated in many cancers, a better understanding of the interactions of drugs with the entire kinome 
would give great insight for more efficacious and safe therapies. 
Four models of LCK are investigated in this study. Although there are experimental structures for 
the kinase domain and the SH1 and SH2 domains of LCK, there are no experimental structures of all 
three of these domains intact. In order to have a more complete structure to obtain more accurate 
dynamics of the protein and have structures to eventually study alternate binding sites that have been 
implicated in kinase drug discover, homology models were built using structures of similar proteins 
with all three domains intact. The 1QCF is of the inactive state using HCK as a template based on 
sequence identity. The 1Y57 model is of the active state using c-SRC as a template since not many 
active structures exist for similar proteins. The 2SRC model is also of the inactive state using c-SRC 
as the template to be consistent with the template for the active model. The 2PL0 model is of the 
inactive state in a DFG-out conformation. A clustering of public human protein kinase structures has 
suggested that the catalytically active structure is similar among kinases and that there are two 
frequently observes inactive states called the “DFG-out” and “C-helix-out” states. In the DFG-out 
state an Asp sidechain that is part of an Asp-Phe-Gly (DFG) motif is rotated out of the ATP binding 
site making a larger pocket. In the C-helix-out state the αC helix is shifted away from the ATP 
binding site making a larger pocket. While other structures of inactive SRC-family kinases adopt the 
C-helix out conformation, a structure of the LCK kinase only domain bound with imatinib, an 
effective treatment of chronic myeloid and gastrointestinal stromal tumors (Lee et al., 2010), suggest 
that the inactive state of LCK may adopt the DFG-out state (Jacobs et al., 2008). This would support 
the finding that imatinib selectively inhibits LCK among SRC-family kinases (Lee et al., 2010) along 
with other kinases shown to adopt the DFG-out inactive conformation. However, there are currently 
no experimental structures for the combined three SH domains for LCK in the active state or locked in 
the inactive state to help support this. 
Using the best enrichment from any cluster and average enrichment over all of the clusters, the 
order of performance of each model with docking scores is, from best to worst, 2SRC, 1QCF, 1Y57, 
and 2PL0. This could indicate that the active compounds preferentially target the inactive state of the 
protein which is normally in the C-helix-out conformation. However, it may sometimes exist in the 
DFG-out conformation, but less and/or different active compounds bind to this conformation. Most 
models have some improvement with the MM/GBSA calculations except for 2SRC which actually 
has decreased performance. Since this model was best performing by docking calculations, it seems 
that this model is well suited for docking and that methods are definitely model dependent. The 
greatest improvement by far is with the 2PL0 model. This could be because the active compounds 
identified in docking truly do bind to the DFG-out conformation and MM/GBSA performed well at 
rescoring these active compounds to this conformation.  
Finally, to test the usefulness of using different conformations, models, and methods, we analyzed 
how many unique compounds are identified with each variation. It can be seen in Figure 4 that each 
variation gives information on different active compounds. Most of the identified actives are common 
with both methods, but a large number of different actives are identified with each method, with 
MM/GBSA recovering more. If you use multiple ways of coming up with a set of compounds to test, 
you will also add to your false positives, and could likely get the same number of positive active 
compounds by just increasing the percent of compounds experimentally tested from an initial 
screening. However, using the approach here may provide insight into how the drug is interacting 
with the protein and provide useful information further down the drug development pipeline. 
5 Conclusions 
Although the MM/GBSA results do not always out perform the docking results, we show here that 
different variations in the drug screening process provide unique results which can be used to better 
understand the biological mechanisms underlying the drug interactions. Of the four models 
investigated, two of them consistently get better results and two get varying results using MM/GBSA. 
Future directions of this work include further tuning of the MM/GBSA calculations. Since the 
MM/GBSA calculations were done on the set of compounds with the best docking score for each 
cluster, the set of compounds with MM/GBSA scores is not consistent across clusters. Future work 
will involve calculations to screen a larger, consistent set of compounds to test if combining 
information across clusters can improve scores. Also, a third tier of increased theoretical accuracy, 
such as with density functional theory is being discussed. 
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